Tenascin-C in the early lung cancer tumor microenvironment promotes progression through integrin αvβ1 and FAK.

Autor: Samson SC; Department of Oncological Sciences, University of Utah, Salt Lake City, UT 84112.; Huntsman Cancer Institute, Salt Lake City, UT 84112., Rojas A; Department of Oncological Sciences, University of Utah, Salt Lake City, UT 84112.; Huntsman Cancer Institute, Salt Lake City, UT 84112., Zitnay RG; Huntsman Cancer Institute, Salt Lake City, UT 84112.; Department of Biomedical Engineering, University of Utah, Salt Lake City, UT 84112., Carney KR; Department of Oncological Sciences, University of Utah, Salt Lake City, UT 84112.; Huntsman Cancer Institute, Salt Lake City, UT 84112., Hettinga W; Huntsman Cancer Institute, Salt Lake City, UT 84112.; Department of Biomedical Engineering, University of Utah, Salt Lake City, UT 84112., Schaelling MC; Department of Oncological Sciences, University of Utah, Salt Lake City, UT 84112.; Huntsman Cancer Institute, Salt Lake City, UT 84112., Sicard D; Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN 55905., Zhang W; Huntsman Cancer Institute, Salt Lake City, UT 84112.; Department of Pathology, University of Utah, Salt Lake City, UT 84112., Gilbert-Ross M; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322., Dy GK; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203., Cavnar MJ; Department of Surgery, University of Kentucky, Lexington, KY 40508., Furqan M; Department of Internal Medicine, University of Iowa Health Care, Iowa City, IA 52246., Browning RF Jr; Department of Medicine, Walter Reed National Military Medical Center, Bethesda, MD 20889., Naqash AR; Division of Medical Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104., Schneider BP; Department of Hematology and Oncology, Indiana University School of Medicine, Indianapolis, IN 46202., Tarhini A; Departments of Cutaneous Oncology and Immunology, H. Lee Moffit Cancer Center & Research Institute, Tampa, FL 33612., Tschumperlin DJ; Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN 55905., Venosa A; Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112., Marcus AI; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322.; Long Island University, College of Veterinary Medicine, Brookville, NY 11548., Emerson LL; Huntsman Cancer Institute, Salt Lake City, UT 84112.; Department of Pathology, University of Utah, Salt Lake City, UT 84112., Spike BT; Department of Oncological Sciences, University of Utah, Salt Lake City, UT 84112.; Huntsman Cancer Institute, Salt Lake City, UT 84112., Knudsen BS; Huntsman Cancer Institute, Salt Lake City, UT 84112.; Department of Pathology, University of Utah, Salt Lake City, UT 84112., Mendoza MC; Department of Oncological Sciences, University of Utah, Salt Lake City, UT 84112.; Huntsman Cancer Institute, Salt Lake City, UT 84112.; Department of Biomedical Engineering, University of Utah, Salt Lake City, UT 84112.

Publikováno v: BioRxiv : the preprint server for biology [bioRxiv] 2024 Sep 21. Date of Electronic Publication: 2024 Sep 21.

Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study.

Autor: Fletcher K; Vanderbilt University School of Medicine, Nashville, USA. Electronic address: kylie.a.fletcher@vanderbilt.edu., Cortellini A; Operative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, 00128, Roma, Italy; Department of Surgery and Cancer, Hammersmith Hospital Campus, Imperial College London, London, United Kingdom., Ganta T; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Kankaria R; Vanderbilt University School of Medicine, Nashville, USA., Song H; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA., Ye F; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA., Irlmeier R; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA., Debnath N; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Saeed A; Division of Hematology & Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA., Radford M; University of Iowa Healthcare, Iowa City, IA, USA., Alahmadi A; Case Western Reserve University, Division of Hematology & Oncology, Cleveland, OH, USA; Ohio State University, The James Comprehensive Cancer Center, Columbus., Diamond A; Case Western Reserve University, Division of Hematology & Oncology, Cleveland, OH, USA; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA., Hoimes C; Case Western Reserve University, Division of Hematology & Oncology, Cleveland, OH, USA; Duke Cancer Institute, Duke University, Durham, NC, USA., Presley CJ; Ohio State University, The James Comprehensive Cancer Center, Columbus., Owen DH; Ohio State University, The James Comprehensive Cancer Center, Columbus., Abou Alaiwi S; Yale New Haven Hospital, Yale School of Medicine, New Haven, CT, USA., Nassar AH; Yale New Haven Hospital, Yale School of Medicine, New Haven, CT, USA., Lamberti G; Department of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, Italy., Perrone F; Medical Oncology Unit, University Hospital of Parma and Medicine and Surgery Department, University of Parma, Parma, Italy., Buti S; Medical Oncology Unit, University Hospital of Parma and Medicine and Surgery Department, University of Parma, Parma, Italy., Giusti R; Medical Oncology Unit, Azienda Ospedaliero Universitaria Sant'Andrea, Rome, Italy., Filetti M; Phase 1 Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy., Vanella V; Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy., Mallardo D; Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy., Sussman TA; Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA., Galetta D; IRCCS Istituto Tumori Giovanni Paolo II, Medical Thoracic Oncology Unit, Bari, Italy., Kalofonou F; Department of Surgery and Cancer, Imperial College London, London, United Kingdom., Daniels E; Department of Surgery and Cancer, Imperial College London, London, United Kingdom., Ascierto PA; Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy., Pinato DJ; Department of Surgery and Cancer, Imperial College London, London, United Kingdom; Department of Translational Medicine, University of Piemonte Orientale 'A. Avogadro', Novara, Italy., Nebhan C; Intermountain Health, Murray UT, USA., Berg S; Dana-Farber Cancer Institute, Boston, MA, USA., Choueiri TK; Dana-Farber Cancer Institute, Boston, MA, USA., Marron TU; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Wang Y; The University of Texas MD Anderson Cancer Center, Houston., Naqash AR; Medical Oncology/TSET Phase 1 Program, Stephenson Cancer Center, University of Oklahoma, Oklahoma City, USA., Johnson DB; Department of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address: douglas.b.johnson@vumc.org.

Publikováno v: Cancer letters [Cancer Lett] 2024 Aug 01; Vol. 596, pp. 217001. Date of Electronic Publication: 2024 Jun 03.

Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States.

Autor: Lurain K; HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. Electronic address: kathryn.lurain@nih.gov., Zarif TE; Yale University School of Medicine, New Haven, CT., Ramaswami R; HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Nassar AH; Yale University School of Medicine, New Haven, CT., Adib E; Brigham and Women's Hospital, Department of Radiation Oncology, Boston, MA., Abdel-Wahab N; MD Anderson Cancer Center, Houston, TX., Chintapally N; Medstar/Georgetown-Washington Hospital Center, Washington, DC., Drolen CE; University of California Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA., Feldman T; John Theurer Cancer Center, Hackensack, NJ., Haykal T; Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC; Ohio State University Comprehensive Cancer Center, Columbus, OH., Nebhan CA; Vanderbilt University Medical Center, Nashville, TN., Thiruvengadam SK; City of Hope Medical Center, Duarte, CA., Li M; Ohio State University Comprehensive Cancer Center, Columbus, OH., Mittra A; Ohio State University Comprehensive Cancer Center, Columbus, OH., Lorentsen M; University of North Carolina, Chapel Hill, NC., Kim C; Medstar Georgetown University Hospital, Washington, DC., Drakaki A; University of California Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA., Morse M; Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC., Johnson DB; Vanderbilt University Medical Center, Nashville, TN., Mangla A; University Hospital Seidman Cancer Center, Cleveland, OH., Dittus C; University of North Carolina, Chapel Hill, NC., Ravi P; Dana-Farber Cancer Institute, Boston, MA., Baiocchi RA; Ohio State University Comprehensive Cancer Center, Columbus, OH., Chiao EY; MD Anderson Cancer Center, Houston, TX., Rubinstein PG; John Stroger Cook County Hospital, Chicago, IL., Yellapragada SV; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine & Michael E. DeBakey VA Medical Center, Houston, TX., LaCasce AS; Dana-Farber Cancer Institute, Boston, MA., Sonpavde GP; Dana-Farber Cancer Institute, Boston, MA., Naqash AR; Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK., Herrera AF; City of Hope Medical Center, Duarte, CA.

Publikováno v: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2024 Aug; Vol. 24 (8), pp. 523-530. Date of Electronic Publication: 2024 Apr 05.

Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study.

Autor: Nassar AH; Department of Medicine (Medical Oncology), Yale School of Medicine, New Haven, Connecticut., Kim SY; Department of Medicine (Medical Oncology), Yale School of Medicine, New Haven, Connecticut., Aredo JV; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California., Feng J; Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre, Toronto, Canada., Shepherd F; Department of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre, Toronto, Canada., Xu C; Department of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma., Kaldas D; Department of Internal Medicine, University of South Florida, Tampa, Florida; Department of Clinical Oncology, Cairo University, Cairo, Egypt., Gray JE; Thoracic Oncology Program, Moffitt Cancer Center, Tampa, Florida., Dilling TJ; Thoracic Oncology Program, Moffitt Cancer Center, Tampa, Florida., Neal JW; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California., Wakelee HA; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California., Liu Y; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Lin SH; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Abuali T; Department of Radiation Oncology, City of Hope National Cancer Center, Duarte, California., Amini A; Department of Radiation Oncology, City of Hope National Cancer Center, Duarte, California., Nie Y; Department of Medicine (Medical Oncology), Yale School of Medicine, New Haven, Connecticut., Patil T; Department of Medicine, University of Colorado Cancer Center, Aurora, Colorado., Lobachov A; Institute of Oncology, Chaim Sheba Medical Center, Ramat Gan, Israel; School of Medicine, Tel Aviv University, Tel Aviv, Israel., Bar J; Institute of Oncology, Chaim Sheba Medical Center, Ramat Gan, Israel; School of Medicine, Tel Aviv University, Tel Aviv, Israel., Fitzgerald B; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Fujiwara Y; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Marron TU; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Thummalapalli R; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Yu H; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York., Owen DH; The Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Sharp J; The Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Farid S; The Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Rocha P; Medical Oncology Department, Hospital del Mar, Barcelona, Spain., Arriola E; Medical Oncology Department, Hospital del Mar, Barcelona, Spain., D'Aiello A; Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York., Cheng H; Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York., Whitaker R; Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee., Parikh K; Mayo Clinic, Rochester, Minnesota., Ashara Y; Mayo Clinic, Rochester, Minnesota., Chen L; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California., Sankar K; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California., Harris JP; Department of Radiation Oncology, University of California Irvine Medical Center, Orange, California., Nagasaka M; Division of Hematology and Oncology, Department of Medicine, University of California Irvine Medical Center, Orange, California., Ayanambakkam A; Oklahoma University, Stephenson Cancer Center, Oklahoma City, Oklahoma., Velazquez AI; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California., Ragavan M; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California., Lin JJ; Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Piotrowska Z; Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Wilgucki M; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC., Reuss J; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC., Luders H; Klinik für Pneumologie-Evangelische Lungenklinik Berlin Buch, Berlin, Germany., Grohe C; Klinik für Pneumologie-Evangelische Lungenklinik Berlin Buch, Berlin, Germany., Baena Espinar J; Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain., Feiner E; Perlmutter Cancer Center, New York University Langone Health, New York, New York., Punekar SR; Perlmutter Cancer Center, New York University Langone Health, New York, New York., Gupta S; Department of Hematology and Medical Oncology, Thoracic Medical Oncology Program, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia., Leal T; Department of Hematology and Medical Oncology, Thoracic Medical Oncology Program, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia., Kwiatkowski DJ; Dana-Farber Cancer Institute, Boston, Massachusetts., Mak RH; Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts., Adib E; Dana-Farber Cancer Institute, Boston, Massachusetts., Naqash AR; Oklahoma University, Stephenson Cancer Center, Oklahoma City, Oklahoma., Goldberg SB; Department of Medicine (Medical Oncology), Yale School of Medicine, New Haven, Connecticut. Electronic address: sarah.goldberg@yale.edu.

Publikováno v: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2024 Jun; Vol. 19 (6), pp. 928-940. Date of Electronic Publication: 2024 Jan 24.

Response letter by Nassar et al.

Autor: Nassar AH; Department of Medicine (Medical Oncology), Yale School of Medicine, New Haven, Connecticut., Kim SY; Department of Medicine (Medical Oncology), Yale School of Medicine, New Haven, Connecticut., Adib E; Dana-Farber Cancer Institute, Boston, Massachusetts., Naqash AR; Oklahoma University, Stephenson Cancer Center, Oklahoma City, Oklahoma., Goldberg SB; Department of Medicine (Medical Oncology), Yale School of Medicine, New Haven, Connecticut. Electronic address: sarah.goldberg@yale.edu.

Publikováno v: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2024 May; Vol. 19 (5), pp. e7-e8.